VIVA Biotech Holdings is a Chinese investment holding company with a primary focus on the biotechnology and pharmaceutical industry. Established in 2008, the company is engaged in the provision of structure-based drug discovery and research services for a range of biotechnology and pharmaceutical clients, with a particular focus on pre-clinical stage drug development. Although headquartered in Shanghai, it has an international client base across the US, China, and Europe.
VIVA Biotech Holdings is listed on the Hong Kong Stock Exchange (HKEX) under the ticker 1873.HK. In 2020, the 1873.HK price chart has displayed a 52-week range of 3.550 HKD to 11.180 HKD, with a current market capitalisation of 15.856bn HKD. Generally, the VIVA Biotech Holdings share sees little in the way of short selling.
The core technologies developed by VIVA Biotech Holdings include a structure-based drug discovery platform, a fragment-based drug discovery platform, an affinity selection mass spectrometry screening platform, and a membrane protein targeted drug discovery platform. Most recently, the company has announced a collaboration strategy with Schrödinger.
To keep track of the VIVA Biotech Holdings share price, add the 1873.HK stock ticker to your eToro trading watchlist to receive all the latest news, information, and price data.